The procoagulant effect of Vitamin-K antagonists in patients with atrial fibrillation, atherosclerosis and deep venous thrombosis

被引：0
|
作者：
Al Dieri, R. [1 ]
ten Cate-Hoek, A. J. [2 ]
ten Cate, H. [2 ]
Hemker, H. C. [1 ]
机构：
[1] Maastricht Univ, Med Ctr, Cardiovasc Res Inst, Synapse Bv, Maastricht, Netherlands
[2] Maastricht Univ, Med Ctr, Dept Internal Med, Maastricht, Netherlands
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2009年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP-WE-683
引用
收藏
页码：857 / 857
页数：1
相关论文
共 50 条
  • [31] ATRIAL FIBRILLATION TREATMENT PARADOX: CHARACTERISTICS OF AND FIRST-YEAR EVENTS IN PATIENTS NOT TREATED WITH VITAMIN-K ANTAGONISTS COMPARED TO TREATED PATIENTS. THE GARFIELD REGISTRY
    Bassand, Jean-Pierre L.
    Rushton-Smith, Sophie
    Camm, A. John
    Goldhaber, Samuel Z.
    Goto, Shinya
    Haas, Sylvia
    Mueller, Iris
    Turpie, Alexander G.
    Kakkar, Ajay
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (10) : E379 - E379
  • [32] Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis
    Natale Daniele Brunetti
    Nicola Tarantino
    Luisa De Gennaro
    Michele Correale
    Francesco Santoro
    Matteo Di Biase
    Journal of Thrombosis and Thrombolysis, 2018, 45 : 550 - 556
  • [33] Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis
    Brunetti, Natale Daniele
    Tarantino, Nicola
    De Gennaro, Luisa
    Correale, Michele
    Santoro, Francesco
    Di Biase, Matteo
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2018, 45 (04) : 550 - 556
  • [34] Pharmacogenetics of vitamin K antagonists and bleeding risk prediction in atrial fibrillation
    Jose Serna, Maria
    Miguel Rivera-Caravaca, Jose
    Gonzalez-Conejero, Rocio
    Asuncion Esteve-Pastor, Maria
    Valdes, Mariano
    Vicente, Vicente
    Lip, Gregory Y. H.
    Roldan, Vanessa
    Marin, Francisco
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2018, 48 (06)
  • [35] Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation
    Cappato, Riccardo
    Ezekowitz, Michael D.
    Klein, Allan L.
    Camm, A. John
    Ma, Chang-Sheng
    Le Heuzey, Jean-Yves
    Talajic, Mario
    Scanavacca, Mauricio
    Vardas, Panos E.
    Kirchhof, Paulus
    Hemmrich, Melanie
    Lanius, Vivian
    LingMeng, Isabelle
    Wildgoose, Peter
    van Eickels, Martin
    Hohnloser, Stefan H.
    EUROPEAN HEART JOURNAL, 2014, 35 (47) : 3346 - 3355
  • [36] ATRIAL-FIBRILLATION AS A RISK FACTOR FOR DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLI IN STROKE PATIENTS
    NOEL, P
    GREGOIRE, F
    CAPON, A
    LEHERT, P
    STROKE, 1991, 22 (06) : 760 - 762
  • [37] Many Good Reasons to Switch from Vitamin K Antagonists to Non-Vitamin K Antagonists in Patients with Non-Valvular Atrial Fibrillation
    Botto, Giovanni Luca
    Ameri, Pietro
    De Caterina, Raffaele
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (13)
  • [38] Comparison of factor X inhibitors versus vitamin K antagonists in atrial fibrillation patients on dialysis
    Chen, Xi
    Zhu, Wengen
    Lin, Meiming
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 127 : 154 - 156
  • [39] Vitamin K antagonists and risk of myelodysplastic syndrome: A nationwide cohort study in atrial fibrillation patients
    Neumann, Anke
    Jabagi, Marie-Joelle
    Zureik, Mahmoud
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 15 - 15
  • [40] To treat or not to treat very elderly na⟨ve patients with atrial fibrillation with vitamin K antagonists
    Dentali, Francesco
    Mumoli, Nicola
    Gianni, Monica
    Cei, Marco
    INTERNAL AND EMERGENCY MEDICINE, 2015, 10 (07) : 765 - 767
12345